Neuroinflammation is a hallmark feature of both Parkinson's Disease Dementia (PDD) and Dementia with Lewy Bodies (DLB), contributing to cognitive decline and disease progression. While these conditions exist on a spectrum of Lewy body disease, the inflammatory component differs in magnitude and pattern compared to Parkinson's disease without dementia, with more prominent cortical and limbic system involvement[1][2].
DLB and PDD share common pathophysiological mechanisms including alpha-synuclein aggregation, cholinergic deficits, and chronic microglial activation. However, the distribution and timing of neuroinflammatory processes distinguish these conditions from both typical Parkinson's disease and Alzheimer's disease[3][4].
In PDD and DLB, microglial activation follows the progression of alpha-synuclein pathology through the brain. Key features include:
The pattern of microglial activation correlates with cognitive impairment severity in both conditions. Post-mortem studies demonstrate that cortical microglial density predicts ante-mortem cognitive scores in DLB patients.
| Cytokine | Change | Clinical Correlation |
|---|---|---|
| IL-1β | Elevated in CSF and brain | Disease severity |
| IL-6 | Elevated in serum/CSF | Cognitive decline rate |
| TNF-α | Elevated in CSF | Motor and cognitive progression |
| IL-8 | Elevated | Neuropsychiatric symptoms |
| IFN-γ | Dysregulated | Fluctuation severity |
BBB dysfunction in PDD/DLB allows peripheral immune cells and inflammatory mediators to enter the CNS:
Anti-inflammatory Strategies:
| Target | Agent | Mechanism | Development Stage |
|---|---|---|---|
| NLRP3 Inflammasome | MCC950, Dapansutrile | Inflammasome inhibition | Preclinical/Phase I |
| TREM2 | AL002, AL003 | Agonist - enhance phagocytosis | Phase II |
| IL-1β | Anakinra, Canakinumab | Receptor blockade | Off-label use |
| TNF-α | XPro1595 | Soluble receptor fusion | Phase II |
| CSF1R | PLX3397 | Microglial depletion | Preclinical |
Immunomodulatory Approaches:
Cholinergic-Inflammatory Axis:
The cholinergic anti-inflammatory pathway is impaired in PDD/DLB. Cholinesterase inhibitors may provide dual benefits:
Neurotrophic Factor Induction:
Fluid Biomarkers:
| Biomarker | Source | Utility |
|---|---|---|
| YKL-40 | CSF | Microglial activation |
| sTREM2 | CSF | TREM2 pathway engagement |
| Neurofilament light (NfL) | Serum | Neurodegeneration rate |
| IL-1β, IL-6 | CSF/serum | Disease activity |
| Alpha-synuclein seeds | CSF | Pathology burden |
Imaging Biomarkers:
Clinical Biomarker Combinations:
Active Trials:
| Trial ID | Phase | Intervention | Target | Status |
|---|---|---|---|---|
| NCT05683439 | Phase 1/2 | Anakinra (IL-1β antagonist) | Neuroinflammation | Recruiting |
| NCT05828813 | Phase 2 | AL002 (TREM2 antibody) | Microglial modulation | Active |
| NCT05526768 | Phase 2 | NLRP3 inhibitor | Inflammasome | Completed |
Completed/Failed Trials:
Motor Symptoms:
Non-Motor Symptoms:
Cognitive Impact:
Neuropsychiatric Symptoms:
Autonomic Dysfunction:
Key Challenges:
Future Directions:
| Feature | DLB | PDD |
|---|---|---|
| Cortical microglial activation | +++ | ++ |
| Temporal lobe inflammation | Prominent | Variable |
| Brainstem involvement | Early | Early |
| Amygdala activation | +++ | ++ |
| Correlation with cognition | Strong | Moderate |
Unlike Alzheimer's disease where neuroinflammation is considered secondary to amyloid pathology, in DLB/PDD, inflammatory processes may be more directly pathogenic:
Hirsch EC, Hunot S. Neuroinflammation in Parkinson's disease. Lancet Neurol. 2009. ↩︎
Janda E, et al. Neuroinflammation in Parkinson's disease - current evidence. Nat Rev Neurol. 2022. ↩︎
McKeith IG, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology. 2020. ↩︎
Emre M, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord. 2007. ↩︎
Bohnen NI, et al. Cholinergic dysfunction in Parkinson's disease and DLB: implications for treatment. Nat Rev Neurol. 2023. ↩︎